Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer

Journal of Clinical Oncology

Volumn 30, Issue 25, 2012, Pages 3071-3076

  Aizer, Ayal A ^a   Paly, Jonathan J ^a   Zietman, Anthony L ^a   Nguyen, Paul L ^b,c   Beard, Clair J ^e   Rao, Sandhya K ^a   Kaplan, Irving D ^d   Niemierko, Andrzej ^a   Hirsch, Michelle S ^b   Wu, Chin Lee ^a   Olumi, Aria F ^a   Michaelson, M Dror ^a   D'Amico, Anthony V ^b,c   Efstathiou, Jason A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Beth Israel Deaconess Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CHARLSON COMORBIDITY INDEX; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK; SINGLE MAN; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; UNITED STATES; UROLOGIST;

ADENOCARCINOMA; AGE FACTORS; AGED; BIOPSY; BOSTON; COMORBIDITY; HUMANS; INTERDISCIPLINARY COMMUNICATION; LOGISTIC MODELS; MALE; MARITAL STATUS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT CARE TEAM; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WATCHFUL WAITING;

EID: 84865743273     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.8466     Document Type: Article

References (29)

1. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011
2. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762-771, 2011
3. Andriole GL, Crawford ED, Grubb RL III, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
4. Hayes JH, Ollendorf DA, Pearson SD, et al: Active surveillance compared with initial treatment for men with low-risk prostate cancer: A decision analysis. JAMA 304:2373-2380, 2010
5. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
6. Thompson IM, Klotz L: Active surveillance for prostate cancer. JAMA 304:2411-2412, 2010
7. Wilt T: VA/NCI/AHRQ Cooperative Studies Program #407. Prostate cancer intervention versus observation trial (PIVOT): Main results from a randomized trial comparing radical prostatectomy to watchful waiting in men with clinically localized prostate cancer. Presented at the 2011 Annual Meeting of the American Urological Association, Washington, DC, May 14-19, 2011 (abstr)
8. Widmark A: Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer. Presented at the 53rd Annual Meeting of the American Society of Radiation Oncology, Miami, FL, October 2-6, 2011 (abstr)
9. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364:1708-1717, 2011
10. Tosoian JJ, Trock BJ, Landis P, et al: Active surveillance program for prostate cancer: An update of the Johns Hopkins experience. J Clin Oncol 29:2185-2190, 2011
11. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
12. van den Bergh RC, Roemeling S, Roobol MJ, et al: Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 55:1-8, 2009
13. Eldefrawy A, Katkoori D, Abramowitz M, et al: Active surveillance vs. treatment for low-risk prostate cancer: A cost comparison. Urol Oncol doi: 10.1016/j.urolonc.2011.04.005 [epub ahead of print on May 24, 2011]
14. Sommers BD, Beard CJ, D'Amico AV, et al: Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113:2058-2067, 2008
15. Davison BJ, Goldenberg SL: Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int 108:1787-1793, 2011
16. Gorin MA, Soloway CT, Eldefrawy A, et al: Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology 77:588-591, 2011
17. Jang TL, Bekelman JE, Liu Y, et al: Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 170:440-450, 2010
18. Bellardita L, Donegani S, Spatuzzi AL, et al: Multidisciplinary versus one-on-one setting: A qualitative study of clinicians' perceptions of their relationship with patients with prostate cancer. J Oncol Pract 7:e1-e5, 2011
19. Gomella LG, Lin J, Hoffman-Censits J, et al: Enhancing prostate cancer care through the multi-disciplinary clinic approach: A 15-year experience. J Oncol Pract 6:e5-e10, 2010
20. Stewart SB, Bañez LL, Robertson CN, et al: Utilization trends at a multidisciplinary prostate cancer clinic: Initial 5-year experience from the Duke Prostate Center. J Urol 187:103-108, 2012
21. ZIP Code Database List: US ZIP Code Database Web site. http://www.zip-codes.com/zip-code-database.asp (accessed April 8, 2012)
22. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
23. Moore MJ, O'Sullivan B, Tannock IF: How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 6:1736-1745, 1988
24. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, et al: Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283:3217-3222, 2000
25. Kasperzyk JL, Shappley WV III, Kenfield SA, et al: Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol 186:1862-1867, 2011
26. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al: Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 183:1786-1791, 2010
27. Burnet KL, Parker C, Dearnaley D, et al: Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int 100:540-543, 2007
28. Corcoran AT, Peele PB, Benoit RM: Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. Urology 76:703-707, 2010
29. Donovan J, Hamdy F, Neal D, et al: Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 7:1-88, 2003